Skip to content skip to primary navi skip to secondary navi skip to meta navi search

Trials

The aims of the GHSG’s current trials are to further optimize first-line treatment in all stages of Hodgkin lymphoma and to improve therapy for relapsed patients, while minimizing treatment-related adverse effects and maintaining treatment efficacy.

Active trials

First-line treatment

Abbreviation Title Stage Trial design
HD17 Treatment optimization trial in the first-line treatment of intermediate stage Hodgkin lymphoma; treatment stratification by means of FDG-PET Intermediate stages Phase III, multicenter, randomized
B-CAP Brentuximab vedotin or B-CAP in the treatment of older patients with newly diagnosed classical Hodgkin lymphoma – a GHSG-NLG Intergroup phase II trial all stages Phase II, multicenter

Treatment of relapses

Abbreviation Title Stage Trial design
HD-R3i A phase II trial to evaluate the safety of RAD001 (everolimus) in combination with DHAP standard chemotherapy in patients with relapsed or refractory Hodgkin lymphoma relapsed / refractory HL, all stages Phase II, multicenter
GHSG-AFM13 An open-label, randomized, multicenter phase II trial with AFM13 in patients with relapsed or treatment-resistant Hodgkin Lymphoma relapsed / refractory HL, all stages Phase II, multicenter, randomized
JeRiCHO JAK-inhibition in recurrent classical Hodgkin Lymphoma: Ruxolitinib in patients with recurrent classical Hodgkin lymphoma – a phase II trial relapsed / refractory HL, all stages Phase II, multicenter